Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Director · Chief Executive Officer | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.68 · Expires 2036-04-14 | Direct | 271,600 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 271,600 · Balance 271,600 F1: 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 16, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 271,600 | $0.00 Strike: $67.68 | $0.00 |
DisclosureSEC source: 0001193125-26-159024 · ownership.xml · derivative · entry 1 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,600 Underlying: Common Stock · 271,600 shares Expires 2036-04-14 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 20:09 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 64,612 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0002007101-26-000004 · form4-03132026_080321.xml · derivative · entry 3 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,612 shares Expires 2031-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is currently vested and exercisable. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 20:09 UTC | CG Oncology, Inc. CGON · Entity 3735 | Tax withholdingCommon Stock | 1,847 | $60.15 | $111,097.05 |
DisclosureSEC source: 0002007101-26-000004 · form4-03132026_080321.xml · nonDerivative · entry 2 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,916 F1 · kind: Represents a "net exercise" of outstanding stock options. The reporting person received 62,765 shares of common stock on net exercise of an option to purchase 64,612 shares of common stock. The Company withheld 1,847 shares of common stock underlying the option and the reporting person paid in cash the delta for payment in full of the aggregate exercise price. This transaction does not represent a sale by the reporting person. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 20:09 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 64,612 | $1.72 | $111,132.64 |
DisclosureSEC source: 0002007101-26-000004 · form4-03132026_080321.xml · nonDerivative · entry 1 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 22:52 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 102,871 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0002007101-26-000002 · form4-03062026_100310.xml · derivative · entry 3 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,612 Underlying: Common Stock · 102,871 shares Expires 2031-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is currently vested and exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 22:52 UTC | CG Oncology, Inc. CGON · Entity 3735 | Tax withholdingCommon Stock | 2,871 | $61.61 | $176,882.31 |
DisclosureSEC source: 0002007101-26-000002 · form4-03062026_100310.xml · nonDerivative · entry 2 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,151 F1 · kind: Represents a "net exercise" of outstanding stock options. The reporting person received 100,000 shares of common stock on net exercise of an option to purchase 102,871 shares of common stock. The Company withheld 2,871 shares of common stock underlying the option and the reporting person paid in cash the delta for payment in full of the aggregate exercise price. This transaction does not represent a sale by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 22:52 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 102,871 | $1.72 | $176,938.12 |
DisclosureSEC source: 0002007101-26-000002 · form4-03062026_100310.xml · nonDerivative · entry 1 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 527,660 | $0.00 Strike: $20.11 | $0.00 |
DisclosureSEC source: 0000950170-25-054742 · ownership.xml · derivative · entry 1 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,660 Underlying: Common Stock · 527,660 shares Expires 2035-04-14 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following April 15, 2025, the vesting commencement date, subject to the Report Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 20:51 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 397,800 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113282 · ownership.xml · derivative · entry 1 Kuan Arthur · CIK 0002007101 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,800 Underlying: Common Stock · 397,800 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following October 4, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.